Clinical trials: Pancreatic Cystic Lesion
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in >80% of cases).
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
- Trial name
- AI-PANC (NCT06638866)
- Testing
- PDAC, Pancreatic precursor lesions
- Where
- 3 sites in China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreatic Cysts
Registry and Fluid Banking of Pancreatic Cystic Lesions
The purpose of this study is to follow patients, who have small mucinous cysts in the pancreas, prospectively over a 5-year period.
- Trial name
- NCT01769534
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Cancer of Pancreas, Pancreas Cyst
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis.
- Trial name
- TEM-PAC (NCT03536793)
- Where
- United Kingdom
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust